What is Cellectar Biosciences' stock price target for 2024?

0 Wall Street research analysts have issued 12-month price targets for Cellectar Biosciences' shares. Their CLRB share price targets range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 292.2% from the stock's current price. View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts .

How have CLRB shares performed in 2023?

Cellectar Biosciences' stock was trading at $1.71 at the start of the year. Since then, CLRB shares have increased by 49.1% and is now trading at $2.55. View the best growth stocks for 2023 here .

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 800,100 shares, a decline of 7.2% from the October 31st total of 861,800 shares. Based on an average trading volume of 708,100 shares, the short-interest ratio is currently 1.1 days. Currently, 6.9% of the company's shares are sold short. View Cellectar Biosciences' Short Interest .

When is Cellectar Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our CLRB earnings forecast .

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.10.

When did Cellectar Biosciences' stock split?

Cellectar Biosciences shares reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM) , Zynga (ZNGA) , Quantum (QTM) , Baytex Energy (BTE) , Sherritt International (S) , Bombardier (BDRBF) , Bombardier, Inc. Class B (BBD.B) , Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM) .

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (6.82%), Worth Venture Partners LLC (2.81%) and Acuta Capital Partners LLC (1.22%). Insiders that own company stock include Dov Elefant, James V Caruso and Jarrod Longcor. View institutional ownership trends .

How do I buy shares of Cellectar Biosciences?

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Cellectar Biosciences Stock Price, News & Analysis (NASDAQ:CLRB)

$2.55

0.00 (0.00%)

(As of 12/6/2023 ET)

Compare

Today's Range: $2.45
▼
$2.62
50-Day Range: $1.94
▼
$2.91
52-Week Range: $1.25
▼
$3.15

Volume: 110,925 shs
Average Volume: 232,270 shs
Market Capitalization: $31.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Cellectar Biosciences MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 292.2% Upside
$10.00 Price Target
Short Interest: Healthy
6.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.85) to ($2.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.32 out of 5 stars

Medical Sector

888th out of 957 stocks

Pharmaceutical Preparations Industry

378th out of 399 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Cellectar Biosciences has a forecasted upside of 292.2% from its current price of $2.55.
Amount of Analyst Coverage
Cellectar Biosciences has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
6.87% of the float of Cellectar Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Cellectar Biosciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cellectar Biosciences has recently decreased by 7.16%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cellectar Biosciences does not currently pay a dividend.
Dividend Growth
Cellectar Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLRB.

0.6

News and Social Media Coverage

News Sentiment
Cellectar Biosciences has a news sentiment score of -0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cellectar Biosciences this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for CLRB on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.60% of the stock of Cellectar Biosciences is held by insiders.
Percentage Held by Institutions
Only 16.41% of the stock of Cellectar Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cellectar Biosciences are expected to grow in the coming year, from ($2.85) to ($2.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cellectar Biosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cellectar Biosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cellectar Biosciences has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cellectar Biosciences Stock (NASDAQ:CLRB)

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

CLRB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLRB Stock News Headlines

December 5, 2023 | finance.yahoo.com

Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe

November 23, 2023 | finance.yahoo.com

Here's Why We're A Bit Worried About Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

December 7, 2023 | Financial Alphas (Ad)

Lithium Discovery So BIG You Can't Miss it, Even From Space

With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!

November 4, 2023 | markets.businessinsider.com

Buy Rating on Cellectar Biosciences: Promising Clinical Study, Fast Track Designation and Strong Financial Position

November 4, 2023 | finance.yahoo.com

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript

November 2, 2023 | msn.com

Cellectar Biosciences Q3 2023 Earnings Preview

November 2, 2023 | finance.yahoo.com

Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024

October 25, 2023 | finance.yahoo.com

Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

December 7, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.

October 24, 2023 | finance.yahoo.com

Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023

October 17, 2023 | finance.yahoo.com

Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

October 7, 2023 | seekingalpha.com

Cellectar Biosciences files to sell 34.5M shares for holders

October 2, 2023 | marketwatch.com

Cellectar Biosciences Shares Rise 10% After Being Granted Four Patents

October 2, 2023 | finance.yahoo.com

Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

September 18, 2023 | finance.yahoo.com

Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia

September 18, 2023 | benzinga.com

Nano-Cap Medical Technology Watchlist (ORHB, BBLG, CLRB, MOVE)

September 11, 2023 | benzinga.com

Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing

September 5, 2023 | marketwatch.com

Cellectar Biosciences Shares Rise 18% After Private Placement Financing

September 5, 2023 | msn.com

Cellectar Biosciences announces up to ~$103M private placement financing

September 5, 2023 | finance.yahoo.com

Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

August 14, 2023 | finanznachrichten.de

Cellectar Biosciences: Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update

August 14, 2023 | finance.yahoo.com

Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update

June 28, 2023 | finance.yahoo.com

Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting

June 27, 2023 | finance.yahoo.com

CLRB - Cellectar Biosciences, Inc.

June 12, 2023 | finance.yahoo.com

Cellectar Provides a Research and Development Program Summary

May 6, 2023 | morningstar.com

UPDATE — Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

May 6, 2023 | seekingalpha.com

Cellectar Biosciences GAAP EPS of -$0.76

See More Headlines

Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2021
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CLRB
CUSIP: N/A
CIK: 1279704
Web: www.cellectar.com
Phone: (608) 441-8120
Fax: 608-441-8121
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +292.2%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -3,821.29%
Return on Assets: -207.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.22
Quick Ratio: 1.22

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.51 per share
Price / Book: 1.69

Miscellaneous

Outstanding Shares: 12,290,000
Free Float: 11,723,000
Market Cap: $31.34 million
Optionable: Not Optionable
Beta: 1.10

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. James V. Caruso (Age 64)
President, CEO & Director
Comp: $846.48k
Mr. Chad J. Kolean CPA (Age 59)
VP, CFO & Secretary
Comp: $453.22k
Mr. Jarrod Longcor (Age 50)
Chief Operating Officer
Comp: $625.32k
Mr. Darrell Shane Lea (Age 50)
Chief Commercial Officer
Dr. Andrei Shustov M.D. (Age 52)
Senior Vice President of Medical

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CLRB Stock Analysis - Frequently Asked Questions

What is Cellectar Biosciences' stock price target for 2024?: 0 Wall Street research analysts have issued 12-month price targets for Cellectar Biosciences' shares. Their CLRB share price targets range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 292.2% from the stock's current price.
View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts.
How have CLRB shares performed in 2023?: Cellectar Biosciences' stock was trading at $1.71 at the start of the year. Since then, CLRB shares have increased by 49.1% and is now trading at $2.55.
View the best growth stocks for 2023 here.
Are investors shorting Cellectar Biosciences?: Cellectar Biosciences saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 800,100 shares, a decline of 7.2% from the October 31st total of 861,800 shares. Based on an average trading volume of 708,100 shares, the short-interest ratio is currently 1.1 days. Currently, 6.9% of the company's shares are sold short.
View Cellectar Biosciences' Short Interest.
When is Cellectar Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our CLRB earnings forecast.
How were Cellectar Biosciences' earnings last quarter?: Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.10.

When did Cellectar Biosciences' stock split?: Cellectar Biosciences shares reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Cellectar Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).
Who are Cellectar Biosciences' major shareholders?: Cellectar Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (6.82%), Worth Venture Partners LLC (2.81%) and Acuta Capital Partners LLC (1.22%). Insiders that own company stock include Dov Elefant, James V Caruso and Jarrod Longcor.
View institutional ownership trends.
How do I buy shares of Cellectar Biosciences?: Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLRB) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial